Gilead to buy East Coast breast cancer-focused biotech in $21 billion deal
September 14, 2020 at 16:12 PM EDT
New Jersey-based Immunomedics' stock jumped 98% midday Monday to $84 per share after the announcement of Gilead's cash offer, which represents a 108% premium to Immunomedics’ closing price on Friday.
